Baker Bros. Advisors LP Bluebird Bio, Inc. Transaction History

Baker Bros. Advisors LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	BUY	$11.24 - $21.0 $25.5 Million - $47.7 Million	2,272,727 Added 1001.25%	2,499,715 $47.8 Million
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $687,830 - $948,455	-25,012 Reduced 9.93%	226,988 $9.82 Million
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $447,719 - $568,750	-13,000 Reduced 4.91%	252,000 $13.6 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $6.1 Million - $10.3 Million	225,000 Added 562.5%	265,000 $16.2 Million
Q4 2018 Feb 13, 2019	SELL	$59.1 - $93.26 $1.15 Million - $1.81 Million	-19,441 Reduced 32.71%	40,000 $3.97 Million
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $12.5 Million - $16.5 Million	-140,559 Reduced 70.28%	59,441 $8.68 Million
Q4 2017 Feb 14, 2018	SELL	$81.25 - $130.7 $3.37 Million - $5.42 Million	-41,441 Reduced 17.16%	200,000 $35.6 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $13.9 Million - $22.1 Million	241,441	241,441 $33.2 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.